211 related articles for article (PubMed ID: 27354181)
21. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity.
Sheldon J; Ramos B; Garcia-Samaniego J; Rios P; Bartholomeusz A; Romero M; Locarnini S; Zoulim F; Soriano V
J Acquir Immune Defic Syndr; 2007 Nov; 46(3):279-82. PubMed ID: 18167643
[TBL] [Abstract][Full Text] [Related]
22. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
Núñez M; Ramos B; Díaz-Pollán B; Camino N; Martín-Carbonero L; Barreiro P; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2006 Sep; 22(9):842-8. PubMed ID: 16989608
[TBL] [Abstract][Full Text] [Related]
23. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
24. Genotyping and molecular characterization of hepatitis B virus from human immunodeficiency virus-infected individuals in southern Africa.
Makondo E; Bell TG; Kramvis A
PLoS One; 2012; 7(9):e46345. PubMed ID: 23029487
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B.
Quarleri J; Moretti F; Bouzas MB; Laufer N; Carrillo MG; Giuliano SF; Pérez H; Cahn P; Salomon H
AIDS Res Hum Retroviruses; 2007 Apr; 23(4):525-31. PubMed ID: 17506609
[TBL] [Abstract][Full Text] [Related]
26. Detection of hepatitis B virus variants in HBV monoinfected and HBV/HIV coinfected Iranian patients under lamivudine treatment.
Aghasadeghi MR; Bahramali G; Sadat SM; Farahani A; Mohraz M; Davar Siadat S; Mostafavi E; Memarnejadian A; Ardestani MS; Vahabpour R; Saraji AA; Delbaz SA
Curr HIV Res; 2011 Jun; 9(4):263-9. PubMed ID: 21671883
[TBL] [Abstract][Full Text] [Related]
27. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
Sheng WH; Hung CC; Chang SY; Liu CJ; Chen MY; Hsieh SM; Kao JH; Chen PJ; Chang SC
Clin Infect Dis; 2012 Feb; 54(4):548-55. PubMed ID: 22156858
[TBL] [Abstract][Full Text] [Related]
28. Short communication: transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals.
Treviño A; Soriano V; Madejon A; Rodriguez C; Barros C; Botecchia M; Tuma P; Del Romero J; de Mendoza C
AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1273-6. PubMed ID: 20001517
[TBL] [Abstract][Full Text] [Related]
29. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
Matthews GV; Avihingsanon A; Lewin SR; Amin J; Rerknimitr R; Petcharapirat P; Marks P; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ
Hepatology; 2008 Oct; 48(4):1062-9. PubMed ID: 18697216
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals.
Cooley L; Ayres A; Bartholomeusz A; Lewin S; Crowe S; Mijch A; Locarnini S; Sasadeusz J
AIDS; 2003 Jul; 17(11):1649-57. PubMed ID: 12853747
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis B virus drug resistance mutations in HIV/HBV co-infected children in Windhoek, Namibia.
Tamandjou Tchuem CR; Brandt L; Nel ER; Cotton MF; Matthews P; Kaindjee-Tjituka F; Preiser W; Andersson MI
PLoS One; 2020; 15(9):e0238839. PubMed ID: 32915862
[TBL] [Abstract][Full Text] [Related]
32. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes.
Svicher V; Gori C; Trignetti M; Visca M; Micheli V; Bernassola M; Salpini R; Gubertini G; Longo R; Niero F; Ceccherini-Silberstein F; De Sanctis GM; Spanò A; Cappiello G; Perno CF
J Hepatol; 2009 Mar; 50(3):461-70. PubMed ID: 19041149
[TBL] [Abstract][Full Text] [Related]
33. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
[TBL] [Abstract][Full Text] [Related]
34. Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.
Kouanfack C; Aghokeng AF; Mondain AM; Bourgeois A; Kenfack A; Mpoudi-Ngolé E; Ducos J; Delaporte E; Laurent C
Antivir Ther; 2012; 17(2):321-6. PubMed ID: 22290198
[TBL] [Abstract][Full Text] [Related]
35. Substantial variation in the hepatitis B surface antigen (HBsAg) in hepatitis B virus (HBV)-positive patients from South Africa: Reliable detection of HBV by the Elecsys HBsAg II assay.
Gencay M; Vermeulen M; Neofytos D; Westergaard G; Pabinger S; Kriegner A; Seffner A; Gohl P; Huebner K; Nauck M; Kaminski WE
J Clin Virol; 2018 Apr; 101():38-43. PubMed ID: 29414186
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
Matthews GV; Bartholomeusz A; Locarnini S; Ayres A; Sasaduesz J; Seaberg E; Cooper DA; Lewin S; Dore GJ; Thio CL
AIDS; 2006 Apr; 20(6):863-70. PubMed ID: 16549970
[TBL] [Abstract][Full Text] [Related]
37. Molecular epidemiology and genotyping of hepatitis B virus of HBsAg-positive patients in Oman.
Al Baqlani SA; Sy BT; Ratsch BA; Al Naamani K; Al Awaidy S; Busaidy SA; Pauli G; Bock CT
PLoS One; 2014; 9(5):e97759. PubMed ID: 24835494
[TBL] [Abstract][Full Text] [Related]
38. The enrichment of HBV immune-escape mutations during nucleoside/nucleotide analogue therapy.
Shan M; Shen Z; Sun H; Zheng J; Zhang M
Antivir Ther; 2017; 22(8):717-720. PubMed ID: 28300730
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi.
Aoudjane S; Chaponda M; González Del Castillo AA; O'Connor J; Noguera M; Beloukas A; Hopkins M; Khoo S; van Oosterhout JJ; Geretti AM
Clin Infect Dis; 2014 Dec; 59(11):1618-26. PubMed ID: 25100867
[TBL] [Abstract][Full Text] [Related]
40. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
